 |
Vol.62 No.2 contents | Japanese/English |
 | Full Text of PDF (1145K) Article in Japanese |
- Case Report -
A Case of Advanced Thymic Carcinoma in Which Carboplatin and Nab-paclitaxel Were Significantly Effective After Progression on Lenvatinib
Remi Mizuta1, Minoru Fukuda1,2, Takayuki Suyama1, Hiroshi Gyotoku1, Shinnosuke Takemoto1, Hiroyuki Yamaguchi1, Toyomitsu Sawai3, Junji Irie4, Kazuto Ashizawa2,5,6, Hiroshi Mukae11Department of Respiratory Medicine, 2Clinical Oncology Center, Nagasaki University Hospital, Japan, 3Department of Respiratory Medicine, 4Department of Pathology, Nagasaki Harbor Medical Center, Japan, 5Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Japan, 6Clinical Genomics Center, Nagasaki University Hospital, Japan
Background. Since there is no insurance-approved drug for thymic carcinoma in Japan, drugs for other cancers are being used provisionally. In 2021, lenvatinib was approved for unresectable thymic carcinoma. Case. A 54-year-old woman visited a nearby doctor with a complaint of left chest pain. Chest CT showed an anterior mediastinal tumor, multiple masses of the left pleura, and left pleural effusion. She was diagnosed with thymic carcinoma (pT2N0M1a, stage IVA) by surgical biopsy. Due to the difficulty of hospitalization due to the COVID-19 pandemic and the wish of the patient, lenvatinib was introduced as the first-line treatment in an outpatient setting. However, her condition worsened and her chest pain increased. When carboplatin and nab-paclitaxel were given as second-line treatment, the tumor in the anterior mediastinum, multiple pleural tumors, and mediastinal lymph nodes were remarkably reduced, the left pleural effusion decreased in volume, and the symptoms were alleviated. Conclusion. We experienced a case in which carboplatin and nab-paclitaxel treatment were effective for advanced thymic carcinoma that was resistant to lenvatinib. Although lenvatinib was newly approved, platinum-based chemotherapy is considered an important option in chemotherapy for thymic carcinoma.
key words: Thymic carcinoma, Lenvatinib, Nab-paclitaxel
Received: September 22, 2021
Accepted: November 18, 2021
JJLC 62 (2): 115-120, 2022
